Bristol-Myers Squibb (BMY) Announces EC Approval for its Sprycel in Combination with Chemotherapy for Treatment of Pediatric Patients with Newly Diagnosed Ph+ ALL

February 11, 2019 7:00 AM
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission (EC) has approved Sprycel (dasatinib) in combination with chemotherapy ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles